Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|February 4, 2021
CTSuccess™ for Efficient Clinical Trial Supply Management
Author(s)Catalent
CTSuccess™ by Catalent employs proactive clinical supply risk evaluation and tailored strategies to ensure on-time start up and efficient material supply throughout clinical studies.
Every clinical trial carries its own unique risks and presents individual challenges, and to overcome these, Catalent launched the CTSuccess™ service, which aligns sponsors’ clinical trial supply needs with the optimal project execution strategy.
CTSuccess employs proactive clinical supply risk evaluation and tailored strategies to support on-time study start-up for small and mid-sized sponsors. CTSuccess features StartScore™, Catalent’s propriety scoring model that evaluates more than 15 common objective and quantifiable study characteristics known to increase project complexity to generate a risk-based score for each project. This enables sponsors to gain advance understanding of the appropriate level of clinical supply management oversight recommended to help ensure their study starts on time and maintains momentum as it progresses.
CTSuccess is used by Catalent’s experts to provide tailored and bespoke solutions to fit the needs of each individual study and reduce the risk of clinical supply related delays and budget overruns through proactive and thoughtful planning.
Catalent’s clinical supply network includes nine cGMP clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local, regional, and global options for clinical packaging, storage, distribution, expiry update, and relabeling services, and clinical returns management.
Catalent
14 Schoolhouse Road Somerset, NJ 08873, USA
tel. +1.888.765.8846
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.